|Bid||102.00 x 800|
|Ask||103.50 x 1400|
|Day's Range||102.42 - 103.88|
|52 Week Range||51.05 - 121.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||123.07|
On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.
Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.
Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.
In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.
Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.
Heron Therapeutics and Intercept Pharmaceuticals could both produce market-crushing returns for investors over the next decade. Here's why.
On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26. On August 6, Intercept Pharmaceuticals’ stock price closed at $114.71, which represents ~125% growth from its 52-week low of $51.05 on February 9.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Biotech stocks Protagonist Therapeutics and Intercept Pharmaceuticals were heading higher on Monday after positive developments and analyst upgrades. Protagonist ...
Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) reported top- and bottom-line beats last week that prompted two Street analysts to upgrade the stock. The Rating Goldman Sachs analyst Salveen Richter upgraded ...
Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price. The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years. Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.
Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.
Intercept Pharmaceuticals Inc. rose to the highest level since September after the company reported increasing sales of its potential blockbuster Ocaliva, a drug previously linked by U.S. officials to the death of 19 people. Sales of Ocaliva, which is approved to treat a rare liver disease called primary biliary cholangitis, climbed to $43.2 million in the second quarter, the New York-based drugmaker said Thursday. In September, Intercept reported 10 deaths in people who had taken the drug.
Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding ICPT totaled $70 million.
The New York-based company said it had a loss of $2.58 per share. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...
Worldwide Ocaliva net sales of $43.2 million in the second quarter of 2018 Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to ...
Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.
NEW YORK, July 26, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...
NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater ...
Biotech stocks have been surging in 2018 as measured by the SPDR S&P Biotech ETF ( XBI), which is up nearly 18%, easily outperforming the S&P 500 rise of 5%. Despite the recent gains, shares of Regeneron Pharmaceuticals, Inc. ( REGN), Seattle Genetics, Inc. ( SGEN) and Intercept Pharmaceuticals, Inc. ( ICPT) may be poised to rise by as much as 20% in the coming weeks based on technical analysis. Based on the technical chart for the Biotech ETF, the sector may increase by another 9%.